E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10005014 |
E.1.2 | Term | Bladder carcinoma |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10005003 |
E.1.2 | Term | Bladder cancer |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10005004 |
E.1.2 | Term | Bladder cancer NOS |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to determine the effect of selenium, in addition to standard care, on the recurrence of bladder cancer. |
|
E.2.2 | Secondary objectives of the trial |
A secondary objective is to determine the effect of the treatment regimens on the recurrence and progression of bladder cancer in terms of histological type, number and size of the tumors in these participants. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Gender: male or female Members of all races and ethnic groups are eligible for this trial. Age: ≥18 Histopathologically confirmed non-muscle-invasive transitional cell carcinoma (< pT2) o Solitary grade 1 pTa 3 cm or larger and all other stage pTa, pT1, or pT carcinoma in situ (cis) o Newly diagnosed disease Able to be randomized within three months of diagnostic transurethral resection of the bladder tumor/biopsy Must meet 1 of the following recurrence risk criteria: o Intermediate risk Multiple G1 pTa (> 1) Solitary G1 pTa (≥ 3 cm) G2 pTa G1 pT1 G2 pT1 (1 or 2 tumours) o High risk G3 pTa G3 pT1 Cis Multiple G2 pT1 (3 or more foci) Must be able to swallow pills Must agree not to take supplements containing selenium apart from the trial medication Fertile female patients must use effective contraception Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
|
|
E.4 | Principal exclusion criteria |
Solitary grade 1, pTa < 3 cm or stage pT2 and above Residual tumors: patients with a recurrence within a period of 3 months after initial treatment (probably due to incomplete resection of the primary index tumor or implantation after the biopsy). Residual tumors have little prospect of being affected by any chemoprevention. Prostatic, prostatic urethral, or upper tract transitional cell carcinoma involvement by the index tumor at resection Advanced disease or muscle invasion Metastatic disease Any other malignancy within the past 5 years Any other serious medical or psychiatric illness that would preclude giving informed consent Known hypersensitivity or adverse reactions to selenium Additional concurrent selenium (contained in individual supplements, antioxidant mix, or multivitamin) intake. Prior daily dietary supplements containing selenium within the last 30 days. Concurrent participation in another study involving a medical, surgical, nutritional, or life-style intervention (unless no longer receiving the intervention and are in the follow-up phase only) Any condition, which, in the opinion of the investigator might interfere with the safety of the patient or the evaluation of the study objectives
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Recurrence-free interval in patients with superficial transitional cell carcinoma of the bladder This is defined as time from date of trial entry to date of recurrence. For those patients who are not observed to have a recurrence by time of analysis, the interval will be censored at the date last-known to be recurrence-free. A recurrence is defined as the new occurrence of a bladder cancer at the same or different site as the initial index primary cancer and excluding tumours identified at the first 3-month check cystoscopy.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |